Informed Decision-Making in HR+ Breast Cancer
Kevin Kalinsky, MD, MS, of Emory Winship Cancer Institute, discusses treatment options for HR-positive/HER2-negative breast cancer and comments on the evolving role of genomic testing in regard to treatment selection.
Recent Videos
Related Content
Treatment Options in Metastatic Castration-Sensitive Prostate Cancer
March 13th 2022Article
In this program Atish D. Choudhury, MD, PhD, discusses recent updates on long-term safety and efficacy data in patients with metastatic castration-sensitive prostate cancer and the importance of patient communication and quality of life while on treatment.
